Penile Length Maintenance Post-Prostatectomy
Phase: NA
Conditions: Prostate Cancer, Penile Diseases
Sponsor: Mayo Clinic

 
 
Penile Length Maintenance 
Post-Prostatectomy  
 
NCT# 03500419 
 
July 3, 2019 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 1 of 19 
Dr. Ziegelmann 
 
 
 
 
PENILE LENGTH MAINTENANCE POST-PROSTATECTOMY 
 
 
Principal Investigator 
 
[Co-Investigator(s)] 
Matthew Ziegelmann, MD 
 
Landon Trost, MD 
Tobias Kohler, MD 
Josh Savage, PA-C 
Elise Tentis, PA-C 
Steve Carlson, APRN, CNP 
 
Funding Sponsor: 
 
Mayo Clinic 
Study Product: 
RestoreX® 
Protocol Number: (IRBe) 
 
 
 
 
 
 
Initial version: January 31, 2018 Version (1.0)  
Revised version:   
April 5, 2018 Version (2.0) 
 
 
May 4, 2018 Version (3.0) 
 
     
November 20, 2018 Version (4.0) 
 
     
April 23, 2019 Version (5.0)  
 
 
July 3, 2019 Version (6.0) 
 
 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 2 of 19 
Dr. Ziegelmann 
 
 
Table of Contents 
STUDY SUMMARY ................................................................................................................................5 
1 
INTRODUCTION ...........................................................................................................................6 
1.1 
BACKGROUND ............................................................................................................................................. 6 
1.2 
INVESTIGATIONAL DEVICE .......................................................................................................................... 6 
1.3 
PRELIMINARY DATA ................................................................................................................................... 7 
1.4 
STUDY RATIONALE AND RISK ANALYSIS (RISKS TO BENEFITS RATIO) ....................................................... 7 
1.4.1 
Study Rationale ....................................................................................................................7 
1.4.2 
Potential Benefits .................................................................................................................7 
1.5 
ANTICIPATED DURATION OF THE CLINICAL INVESTIGATION ....................................................................... 8 
2 
STUDY OBJECTIVES ....................................................................................................................8 
2.1 
PRIMARY OBJECTIVE .................................................................................................................................. 8 
2.2 
SECONDARY OBJECTIVE ............................................................................................................................. 8 
3 
STUDY DESIGN .............................................................................................................................8 
3.1 
SUBJECT SELECTION ................................................................................................................................... 9 
3.1.1 
Inclusion Criteria .................................................................................................................9 
3.1.2 
Exclusion Criteria ................................................................................................................9 
3.2 
SETTING ...................................................................................................................................................... 9 
3.3 
RECRUITMENT............................................................................................................................................. 9 
3.4 
CONSENT AND ENROLLMENT ...................................................................................................................... 9 
3.5 
STUDY SCHEMA ........................................................................................................................................ 10 
3.6 
RANDOMIZATION PROTOCOL .................................................................................................................... 11 
4 
STUDY PROCEDURES............................................................................................................... 11 
4.1 
PRE-OPERATIVE ASSESSMENTS ................................................................................................................ 11 
4.2 
BASELINE ASSESSMENT ............................................................................................................................ 11 
4.3 
6 MONTH VISIT ......................................................................................................................................... 12 
4.4 
9 MONTH VISIT ......................................................................................................................................... 12 
4.5 
ASSESSMENT OF LENGTH .......................................................................................................................... 12 
4.6 
SCHEDULE OF EVENTS .............................................................................................................................. 12 
5 
STATISTICAL PLAN .................................................................................................................. 13 
5.1 
DATA HANDLING ...................................................................................................................................... 13 
5.2 
STATISTICAL ANALYSIS ............................................................................................................................ 13 
6 
SAFETY AND ADVERSE EVENTS ............................................................................................ 14 
6.1 
ADVERSE EVENT REPORTING PERIOD ....................................................................................................... 15 
6.2 
PREEXISTING CONDITION .......................................................................................................................... 15 
6.3 
POST-STUDY ADVERSE EVENT .................................................................................................................. 15 
6.4 
HOSPITALIZATION, PROLONGED HOSPITALIZATION OR SURGERY............................................................. 15 
6.5 
RECORDING OF ADVERSE EVENTS ............................................................................................................ 15 
6.6 
REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS .......................................... 16 
6.6.1 
Sponsor-investigator Reporting: Notifying the Mayo IRB ..................................................... 16 
6.6.2 
Stopping Rules .................................................................................................................. 16 
6.6.3 
Medical Monitoring .......................................................................................................... 17 
7 
DATA HANDLING AND RECORD KEEPING ........................................................................... 17 
7.1 
CONFIDENTIALITY..................................................................................................................................... 17 
7.2 
SOURCE DOCUMENTS................................................................................................................................ 17 
7.3 
RECORDS RETENTION ............................................................................................................................... 17 
8 
STUDY FINANCES ..................................................................................................................... 18 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 3 of 19 
Dr. Ziegelmann 
 
 
8.1 
FUNDING SOURCE ..................................................................................................................................... 18 
8.2 
CONFLICT OF INTEREST ............................................................................................................................. 18 
8.3 
SUBJECT STIPENDS OR PAYMENTS ............................................................................................................ 18 
8.4 
REGULATORY INFORMATION .................................................................................................................... 18 
9 
REFERENCES ............................................................................................................................ 19 
 
 
 
 
 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 4 of 19 
Dr. Ziegelmann 
 
 
 
LIST OF ABBREVIATIONS 
 
AE 
Adverse Event/Adverse Experience 
HIPAA 
Health Insurance Portability and Accountability Act 
PTT 
PD 
Penile traction therapy 
Peyronie’s Disease 
RCT 
Randomized controlled trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 5 of 19 
Dr. Ziegelmann 
 
 
Study Summary 
Title 
Penile Lengthening Maintenance Post-prostatectomy  
IRB Protocol 
Number 
18-001013 
Methodology 
Controlled randomized study 
Overall Study 
Duration 
3 years 
Subject Participation 
Duration 
9 months 
Objectives 
Evaluate the efficacy of the RestoreX penile traction device in 
preventing loss of penile length in men undergoing prostatectomy 
Number of Subjects 
90 
Diagnosis and Main 
Inclusion Criteria 
Men undergoing prostatectomy  
Study Device 
RestoreX®, penile traction therapy 
Duration of 
Exposure 
Subjects will use device for 5 months for: 
30 minutes, once daily, 5 days a week  
OR 30 minutes, twice daily, 7 days a week 
 
After the randomized period, all subjects will be entered into an open-
label phase where they may choose to use or not use the device for 3 
additional months 
Reference therapy 
During the randomized phase, the use of the device will be compared 
against a control group using no traction therapy 
 
In the open label phase, results at the end of 9 months will be 
compared to those from baseline and at the beginning of the open 
label phase 
Statistical 
Methodology 
Stratification of subjects prior to randomization to assure an equal 
representation based on baseline penile length.  Statistical 
comparisons will be made comparing total penile length prior to and 
following therapy.  Comparisons of subjective questionnaire 
responses will also be made between groups and at the various time 
points captured.  
 
 
 
 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 6 of 19 
Dr. Ziegelmann 
 
 
1 Introduction 
 
This document is a protocol for a human research device study. This study will be carried out 
in accordance with the procedures described in this protocol, applicable United States 
government regulations and Mayo Clinic policies and procedures.  
1.1 
Background 
 
The treatment of prostate cancer results in several known sexual dysfunctions, including 
erectile dysfunction, orgasmic dysfunction, ejaculatory dysfunction, penile curvature 
(Peyronie’s disease), and reduced penile length.  Although all forms of prostate cancer 
treatment are associated with many of these changes, prostatectomy currently has the most 
data available on sexual function outcomes.  Among the dysfunctions, loss of penile length is 
often one that results in significant distress and bother to patients.  Beyond the esthetic 
concerns, reduced penile length may lead to inability to participate in sexual intercourse, 
difficulty with future interventions to restore erectile function (placement of a penile 
prosthesis), and lead to worsened urinary hygiene (leak urine onto self, leading to yeast 
infections and other issues).   
 
Penile traction therapy (PTT) is currently the best available treatment to maintain or restore 
lost penile length due to conditions that reduce length.1  Prior studies evaluating penile length 
maintenance post-prostatectomy have utilized a vacuum erection device with varying rates of 
efficacy.  However, to date, no studies have evaluated the benefits of using PTT in this 
clinical setting.  The objective of the current study is to evaluate the efficacy of a novel, 
Mayo-clinic developed PTT device in maintaining (randomized phase) or restoring (open 
label phase) reduced penile length.   
1.2 
Investigational Device 
 
RestoreX is a PTT device developed by PathRight Medical using technology licensed from 
the Mayo Clinic.  The device is classified as class I (orthotic) and does not require clinical 
trials to prove safety or efficacy.  Mayo Clinic is currently conducting a randomized clinical 
trial to evaluate several clinically relevant factors including safety, comfort, and preference 
and to provide preliminary data on dosing and efficacy (IRB 17-001283).   
 
The device has two functional aspects.  The first is the ability to provide direct traction on the 
penis.  The second is the ability to provide counter-bending forces, to treat conditions such as 
Peyronie’s disease (bent penis).  In the current study, only the direct traction aspects of the 
device will be investigated.   
 
Men randomized to treatment will be recommended to utilize the device for 5 months for 30 
minutes, once daily, 5 days per week or 30 minutes, twice daily, 7 days per week after 
undergoing a prostatectomy.   
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 7 of 19 
Dr. Ziegelmann 
 
 
After the initial randomized phase, all patients will enter an open-label phase where they may 
use the device as little or as much as they choose for a period of 6 months.   
 
1.3 
Preliminary Data 
 
Currently, there is a small amount of preliminary data available on the RestoreX® 
instrument.  During the developmental phase of the device, a quality improvement project 
was performed to evaluate the clamping portion.  It was determined that the clamp 
represented the most critical aspect of the device, as this was where the majority of 
discomfort occurred with other devices.  Additionally, the clamp needed to provide sufficient 
friction to allow adequate traction without having the glans of the penis dislodge from the 
device.   
 
A total of 15 patients participated in the quality improvement project and had the clamps 
applied under direct supervision for 30 minutes. After the 30 minutes, all patients reported 
0/10 pain, and only minimal transient erythema was documented by the physician.  The 
clamp was again applied, and traction forces were administered to determine if the clamp 
was able to remain intact despite stretching forces applied.  This also resulted in a successful 
outcome, with all patients able to successfully achieve a minimum required tension of 1 kg, 
with a 36% safety factor achieved before any discomfort was reported among any patient.  
During the testing, patients reported improved comfort with the use of a wrap such as gauze 
or Coban, which permitted additional traction in all patients.   
 
Regarding background data on the RestoreX device, currently, Mayo Clinic is conducting a 
randomized clinical trial evaluating its role in men with PD (IRB 17-001283).  Initial data are 
expected by the end of 2018.   
1.4 
Study Rationale and Risk Analysis (Risks to Benefits Ratio) 
1.4.1 Study Rationale 
 
PTT has been shown to improve penile length in several clinical scenarios, including 
following penile surgery, as a primary lengthening therapy, and in men with conditions 
which shorten the penis such as Peyronie’s disease.  To date, no studies have evaluated the 
role of PTT in maintaining and restoring penile length in men undergoing prostatectomy for 
prostate cancer.  The current study is designed to address this gap in the literature.   
1.4.2 Potential Benefits 
 
There are several potential benefits to using PTT following prostatectomy.  As loss of penile 
length results in several issues including loss of sexual function, cosmetic concerns, and 
difficulty in maintaining hygiene (incontinence resulting in yeast infections), the ability to 
maintain or restore length post-prostatectomy may mitigate these issues.  Additionally, 
following prostatectomy, an increased percentage of men experience penile curvature 
(Peyronie’s disease [PD]), which can be both functionally and psychologically distressing.  

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 8 of 19 
Dr. Ziegelmann 
 
 
PTT has previously been demonstrated to limit the extent of penile curvature that men 
experience among those with early PD, and therefore, the use of PTT early in the post-
prostatectomy phase may reduce the likelihood of either developing the condition or in 
lessening the extent of the condition.  It is not expected that the use of PTT will impact 
(improve or worsen) erectile rigidity post-prostatectomy or impact orgasmic or ejaculatory 
dysfunctions.   
1.5 
Anticipated Duration of the Clinical Investigation 
 
The overall study will be scheduled for 3 years, to permit adequate time for enrollment and 
follow-up.  The intervention phase will include 5 months of randomized treatment (for the 
treatment arm), 3 months of open label treatment (for all arms) and up to 12 months post-
prostatectomy follow-up.   
 
2 Study Objectives 
 
2.1 
Primary Objective 
 
1. The primary objective is to assess penile length pre and post completion of RestoreX® 
traction therapy compared to control groups (no treatment) of subjects who have undergone  
a prostatectomy.  
 
 
2.2 
Secondary Objectives 
 
1. Compare patient compliance with traction device. 
2. Compare patient reported satisfaction with use of traction device. 
3. Evaluate any adverse events (AEs) with use of RestoreX® for penile lengthening.  
4. Compare the rate of Peyronie’s disease development among groups  
5. Compare patient satisfaction scores including satisfaction with overall penile length. 
6. Evaluate and compare patient erectile function among groups 
7. Compare penile length outcomes pre- and post-open phase traction therapy 
8. Evaluate the duration of treatment utilized during the open phase of treatment 
9. Review associations between pre-surgical factors (demographics, disease-specific factors, 
and standardized questionnaires) and outcomes 
 
 
3 Study Design 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 9 of 19 
Dr. Ziegelmann 
 
 
3.1 
Subject Selection 
3.1.1 Inclusion Criteria 
 
• Undergoing  prostatectomy 
• >18 years old 
• Seen in the post-prostatectomy rehab clinic 
3.1.2 Exclusion Criteria 
 
• Urethral complications from prostatectomy at the time of baseline visit 
o Complications include contrast extravasation, anastomotic dehiscence of 
vesicourethral anastomosis, need for re-doing of vasicourethral anastomosis 
intra-operatively 
 
3.2 
Setting 
 
The current study will be conducted at the Mayo Clinic in Rochester, MN Department of 
Urology.  All patients will be recruited from the post-prostatectomy rehab clinic. 
 
3.3 
Recruitment  
Patients attending the post-prostatectomy rehabilitation clinic will be notified of the study 
and offered participation if meeting inclusion / exclusion criteria.  Patients will then be given 
up to one month post-prostatectomy to decide whether or not they would wish to enroll.  
Those interested in proceeding with the trial will be invited to meet with a study coordinator. 
At this time, the details of the study itself will be reviewed with the potential participant. No 
financial incentives will be provided to participate in the trial; however, participants would 
be given a RestoreX® device at no charge. Patients will not be charged for any visits related 
to the study, and no labs or other testing will be obtained which require payment.   
 
Patients will also be provided with a recruitment flyer by the physician, resident or physician 
assistant they are seeing during their standard clinic appointment prior to their prostatectomy 
procedure. This provides patients with additional time to consider the research study. Those 
interested will be encouraged to reach out to the study coordinator for additional information.  
 
3.4 
Consent and Enrollment 
 
Patients attending a penile rehabilitation clinic (either prior to or following surgery) will 
receive a description of the study. Those interested in participating, will be given the 
opportunity to meet with the study coordinator to further review study details and formal 
consent.  
Patients that would like additional time to consider their participation will be given another 
opportunity to meet with the study coordinator up to one month following the prostatectomy.   

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 10 of 19 
Dr. Ziegelmann 
 
 
If the patient expresses interest in participating at any of these times, a formal consent will be 
reviewed (see Attachment – Consent Form).  
 
At enrollment, all participants will be assigned a study identifier, with a master list 
maintained in a password protected database (Mayo server) linking the patient to the 
identifier. A total of 30 patients will be enrolled into each arm of the study, for a total of 90 
patients enrolled overall. It is estimated that 100 patients will need to be screened to enroll 
the 90 patients. 
 
3.5 
Study Schema 
 
Prior to surgery, data will be recorded by the surgeon using the current standard of care 
questionnaires (EPIC-50, IIEF-15 disease specific variables, and demographics).  
 
Following surgery, patients will be seen in the clinic based on the standard routine clinical 
practice for their catheter removal (approximately 1-3 weeks post-prostatectomy). At this 
time, and after the patient has consented, they will undergo initial study penile length 
assessments (described later in the protocol) and be educated on how to use the device 
properly by a trained nurse. Patients will then be given a baseline questionnaire to complete. 
In some cases, patients may not have been provided the IIEF-15 questionnaire prior to 
surgery. For these patients that have not yet filled out this questionnaire and had their data 
recorded in their records, they will instead receive the IIEF-15 questionnaire during this 
baseline visit. 
 
Once consent and study assessments are completed, the patients will be randomized into one 
of three groups:  
1. PTT for 30 min 1x/day, 5days/week 
2. PTT for 30 min 2x/day, 7 days/week   
3. Control (no treatment) 
 
Patients in the treatment arm will record a daily journal of their usage of the device. Patients 
will then begin using the device 4 weeks after surgery as instructed for the times appropriate 
to their group. This ensures adequate time for the patient to recover from their procedure 
before beginning to use the device. The study coordinator will call the patient to remind them 
to begin using the device.   
 
After 5 months of using the device (+1.5 months permitted), patients will return for 
subsequent assessments (see below) and a follow-up questionnaire. At this time, patients will 
be encouraged to report any adverse events. They will also be requested to bring their device 
back to the clinic to review proper usage and any questions on the device. After completion 
of the subsequent assessments, patients will begin a 3-month, open-label phase of the trial.  
During this period, the patients will be allowed to use the device for 30 minutes at a time, 
with a frequency to be determined by the patient.   
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 11 of 19 
Dr. Ziegelmann 
 
 
After completion of the 3-month open-phase portion of the trial, patients will return to the 
clinic to undergo final assessments, which are identical to the 6-month assessments.  Patients 
will then be encouraged to self-report any additional adverse events (AE’s) that they 
encounter over the subsequent 6 months. 
 
Since participants are being asked to travel to Mayo Clinic for subsequent assessments, we 
will provide a remuneration amount of up to $600. The purpose is to assist participants in 
their travel to and from Mayo Clinic. Those that provide consent will be provided $100 after 
their baseline assessment. After their second visit, 6 months post-procedure, they will receive 
$250. After their third visit, 9 month post-procedure, they will receive $250.   
 
If patients are unable to travel back to Mayo Clinic for their 6 and 9 month follow up visit, 
but are still willing to participate in the study, we will ask them to complete the 6 and 9 
month questionnaires via letter mail and return it to Mayo Clinic along with their usage diary.  
 
3.6 
Randomization Protocol 
 
Following enrollment and completion of the initial length assessment, patients will be 
categorized into the appropriate strata based on their baseline stretched penile length; strata 
categorized as <10 cm, 10cm-13cm, 13.1cm-16cm, >16cm stretched length. Each stratum 
will have a separate randomization table provided such that one of three possible outcomes 
will occur no less frequently than every other case. This is done to better account for baseline 
variables that may impact outcomes and to assist with matching groupings appropriately.   
 
The explanation of which grouping the patient is assigned will then be reviewed, and if the 
patient subject is assigned to the treatment group, a RestoreX® device will be provided.  
 
4 Study Procedures 
 
4.1 
Pre-Operative Assessments 
• 
Captured as a function of standard care  
o EPIC-50 
o IIEF-15 
o Disease specific variables 
o Demographics 
• 
Participant consented 
 
4.2 
Baseline Assessment 
 
• Participant consented (if they were not originally consented at the pre-operative 
appointment) 
• Obtained prior to randomization at time of catheter removal (part of standard care) 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 12 of 19 
Dr. Ziegelmann 
 
 
• Objective assessments  
o Penile length – measured from pubic symphysis to glanular corona 
• Subjective questionnaires (attached)  
o Disease specific history 
o IIEF-15 (for patients who have not completed pre-operatively) 
• Device usage diary provided for treatment group 
 
4.3 
6 Month Visit 
 
• Penile length assessment 
• Questionnaires (attached) 
o 6 month 
o IIEF-15 
• Device usage diary retrieved from treatment group 
• Device usage diary given to all participants (enter open label phase) 
 
4.4 
9 Month Visit 
 
• Penile length assessment 
• Questionnaire  
o 9 month  
o IIEF-15  
• 
Retrieve device usage diary 
 
4.5 
Assessment of Length 
Penile length measurements will be obtained by a member of the clinical team using a 
measurement from the pubic symphysis to the corona of the glans penis.  Measurements will 
be obtained post-operatively (after catheter removal) and at the 6 and 9 month follow-ups.   
 
See Attachments – Device Usage Diary, Disease Specific History, IIEF-15, 
Questionnaire 6 Month and 9 Month 
 
4.6 
Schedule of Events 
 
Table 1: Schedule of Events  
 
Study Activity 
Pre-
operative 
Baseline 
Assessment 
6 Month 
 
9Month 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 13 of 19 
Dr. Ziegelmann 
 
 
(post-
operative 
up to 1 mo) 
 
 
 
 
 
 
Consent 
X 
X 
 
 
EPIC-50 
X 
 
 
 
IIEF-15 
X 
X 
X 
X 
Disease Specific History 
 
X 
 
 
Length Assessment 
 
X 
X 
X 
Patient Diary Provided  
 
X 
X 
 
Questionnaire 6 Month 
 
 
X 
 
Questionnaire 9Month 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Statistical Plan 
5.1 
Data Handling 
 
All data will be recorded either by the patient themselves or by the provider directly onto 
printed forms (Attachments).  Information will remain de-identified throughout the 
remainder of the study period and will remain on password protected, Mayo servers.   
 
After completion of the study, de-identified information will be shared with individuals 
associated with PathRight Medical, Inc. who may assist with portions of the data analysis 
and/or manuscript drafting.  No identifiable information will be sent.   
 
5.2 
Statistical Analysis 
 
Analyses will be performed using comparisons within patients of same baseline penile stretch 
length and between groupings of varying lengths. Comparison of penile length between 
traction and no traction will be made, as well as reviewing historical records to increase 
statistical power. Comparison of length from baseline to post-traction for individual 
participants will also be reviewed.   
 
The data will also be analyzed in three ways: 1- with all patients included, regardless of their 
compliance to utilize the device for the recommended treatment time, 2- with patients 
excluded if they failed to achieve 90% compliance with the recommended duration of 
treatment, 3- with patients excluded if they failed to achieve 80% compliance with the 
recommended duration of treatment. 
Comparisons will also be made on other subjective and objective variables obtained 
including number of adverse events, complications, subjective responses to questionnaires, or 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 14 of 19 
Dr. Ziegelmann 
 
 
other information.  All data will be normalized based on pre-operative stretched penile 
length.   
 
6 Safety and Adverse Events 
 
Definition of Adverse Event 
 
Unanticipated Problems Involving Risk to Subjects or Others (UPIRTSO) - any 
unanticipated problem or adverse event that meets the following three criteria:  
 
Serious: Serious problems or events that results in significant harm, (which may be physical, 
psychological, financial, social, economic, or legal) or increased risk for the subject or others 
(including individuals who are not research subjects). These include: (1) death; (2) life 
threatening adverse experience; (3) hospitalization - inpatient, new, or prolonged; (4) 
disability/incapacity - persistent or significant; (5) breach of confidentiality and (6) other 
problems, events, or new information (i.e. publications, interim findings, product labeling 
change) that in the opinion of the local investigator may adversely affect the rights, safety, or 
welfare of the subjects or others, or substantially compromise the research data, AND 
 
Unanticipated: (i.e. unexpected) problems or events are those that are not already described 
as potential risks in the protocol, consent document, not listed in the Investigator’s Brochure, 
or not part of an underlying disease. A problem or event is "unanticipated" when it was 
unforeseeable at the time of its occurrence. A problem or event is "unanticipated" when it 
occurs at an increased frequency or at an increased severity than expected, AND 
 
Related: A problem or event is "related" if it is possibly related to the research procedures. 
 
Adverse Event - an untoward or undesirable experience associated with the use of a medical 
product (i.e. drug, device, biologic) in a patient or research subject. 
 
Serious Adverse Event - adverse events are classified as serious or non-serious.  Serious 
problems/events can be well defined and include: 
 
• 
Death 
• 
Life threatening adverse experience 
• 
Hospitalization 
• 
Inpatient, new, or prolonged; disability/incapacity 
• 
And/or per protocol may be problems/events that in the opinion of the sponsor-
investigator may have adversely affected the rights, safety, or welfare of the subjects or 
others, or substantially compromised the research data. 
 
All AEs that do not meet any of the criteria for serious, should be regarded as non-serious 
AEs.  
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 15 of 19 
Dr. Ziegelmann 
 
 
6.1 
Adverse Event Reporting Period 
 
For the current study, the treatment follow-up period is defined as 3 months following the 
last administration of study treatment. 
6.2 
Preexisting Condition 
 
A preexisting condition is one that is present at the start of the study.  A preexisting condition 
should be recorded as an adverse event if the frequency, intensity, or the character of the 
condition worsens during the study period. 
 
At screening, any clinically significant abnormality should be recorded as a preexisting 
condition.  At the end of the study, any new clinically significant findings/abnormalities that 
meet the definition of an adverse event must also be recorded and documented as an adverse 
event.  
 
6.3 
Post-study Adverse Event 
 
All unresolved AEs will be followed by the study team until the events are resolved, the 
subject is lost to follow-up, or the AE is otherwise explained.  A review of AEs which the 
subject or subject’s physician believe might reasonably be related to participation in the 
study will be performed up to 9 months following surgery.   
 
6.4 
Hospitalization, Prolonged Hospitalization or Surgery 
 
Any AE related to the study intervention that results in hospitalization or surgery should be 
documented and reported as a serious AE.   
 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as 
an adverse event in the following circumstances:  
• 
Hospitalization or prolonged hospitalization for diagnostic or elective surgical 
procedures for a preexisting condition.  Surgery should not be reported as an outcome of an 
adverse event if the purpose of the surgery was elective or diagnostic and the outcome was 
uneventful. 
 
6.5 
Recording of Adverse Events 
 
The study team will seek information on adverse events by specific questioning between 
baseline and the followup visits.  Information on all adverse events will be recorded 
immediately in the adverse event section of the specific questionnaire as well as in an 
adverse event form (see Attachment – Adverse Event Form). 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 16 of 19 
Dr. Ziegelmann 
 
 
All adverse events occurring during the study period will be recorded.  The clinical course 
will be followed until resolution, stabilization, or until it has been ultimately determined that 
the study treatment or participation is not the probable cause.  Serious adverse events that are 
still ongoing at the end of the study period will be followed up, to determine the final 
outcome.  Any serious adverse event that occurs after the study period and is considered to 
be at least possibly related to the study treatment or study participation will be recorded and 
reported immediately. 
 
6.6 
Reporting of Serious Adverse Events and Unanticipated Problems 
 
When an adverse event has been identified, the study team will take appropriated action 
necessary to protect the study participant and then complete the Adverse Event Form.  The 
sponsor-investigator will evaluate the event and determine the necessary follow-up and 
reporting required. 
 
6.6.1 Sponsor-investigator Reporting: Notifying the Mayo IRB 
 
An adverse event form will be completed for any serious adverse event.  This will be 
reported to the Mayo IRB in a de-identified manner.   
 
The study team will report to the Mayo IRB any UPIRTSOs and Non-UPIRTSOs according 
to the Mayo IRB Policy and Procedures. 
 
Information collected on the adverse event form (and entered into the research database)  
• 
Subject’s ID 
• 
Description of adverse event 
• 
The date the adverse event occurred and resolved (if applicable) 
• 
Intensity 
• 
Outcome 
• 
Action taken to address 
• 
Relationship to study 
• 
Impact on study withdrawal 
• 
Classification as serious or not 
 
The sponsor-investigator will review all adverse event reports to determine if specific reports 
need to be made to the IRB.  The sponsor-investigator will sign and date the adverse event 
report when it is reviewed.  For this protocol, only directly related SAEs/UPIRTSOs will be 
reported to the IRB. 
 
6.6.2 Stopping Rules 
 
Any serious adverse event which is determined to reasonably be related to the study device 
by the sponsor-investigator will result in immediate discontinuation of the therapy.  If 5 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 17 of 19 
Dr. Ziegelmann 
 
 
patients develop serious adverse events, the study will be halted with re-review required by 
the Mayo IRB prior to consideration of study resumption.   
 
6.6.3 Medical Monitoring 
 
Medical monitoring of serious adverse events will be performed by the study investigator on 
a monthly-basis if serious adverse events have been reported.   
 
 
7 Data Handling and Record Keeping 
7.1 
Confidentiality 
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the 
following: 
• What protected health information (PHI) will be collected from subjects in this study 
• Who will have access to that information and why 
• Who will use or disclose that information 
• The rights of a research subject to revoke their authorization for use of their PHI. 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of 
subject authorization.  For subjects that have revoked authorization to collect or use PHI, 
attempts should be made to obtain permission to collect at least vital status (long term 
survival status that the subject is alive) at the end of their scheduled study period. 
7.2 
Source Documents 
 
Source data comprise all information, original records of clinical findings, observations, or 
other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents.  Examples of these original documents, and 
data records include: hospital records, clinical and office charts, laboratory notes, 
memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copies or transcriptions certified after verification 
as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic 
media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at 
medico-technical departments involved in the clinical trial. When applicable, information 
recorded on the CRF shall match the Source Data recorded on the Source Documents. 
 
 
7.3 
Records Retention 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 18 of 19 
Dr. Ziegelmann 
 
 
The sponsor-investigator will maintain records and essential documents related to the 
conduct of the study.  These will include subject case histories and regulatory documents. 
 
The sponsor-investigator will retain the specified records and reports during the study and for 
the longer of the following; 
1. As outlined in the Mayo Clinic Research Policy Manual –“Retention of and Access to 
Research Data Policy” http://mayocontent.mayo.edu/research-policy/MSS_669717,  
 
OR 
 
2. A period of 2 years after the latter of the following two dates: The date on which the 
investigation is terminated or completed, or the date that the records are no longer 
required for purposes of supporting a premarket approval application or a notice of 
completion of a product development protocol. 
 
8 Study Finances 
8.1 
Funding Source 
This study is a Mayo Funded study.  
8.2 
Conflict of Interest 
 
Dr. Landon Trost is the inventor and developer of the RestoreX® device.  His conflict has 
previously been reviewed with the Mayo Clinic Conflict of Interest Review Board, and 
following review, it has been determined that Dr. Trost is able to conduct these studies as a 
Primary Investigator (IRB17-001283).   
8.3 
Subject Stipends or Payments 
 
Subjects will not receive payment for their participants; however, they will be able to keep 
the study device following completion of the study.  
 
8.4 
Regulatory Information 
 
PathRight Medical has registered the RestoreX® device with the FDA as a Class I device, 
similar to limb orthotics (see Attachment – RCRI Position Paper).  The device is available 
without a prescription and may be purchased by the general public.  As such, clinical studies 
are not required prior to its routine use, and the current studies are being done as an 
investigator-initiated project to determine its potential role in length of penile prosthesis 
inserted.   
 
 
 

IRB: 18-001013 
 
Version 6.0 
 
 
Revised 7/3/2019 
 
Page 19 of 19 
Dr. Ziegelmann 
 
 
9 References 
 
  
 
1. 
Trost, L. W., Munarriz, R., Wang, R. et al.: External Mechanical Devices and 
Vascular Surgery for Erectile Dysfunction. J Sex Med, 13: 1579, 2016